MUC16 and neoplasm: Another MUC16-targeting agent currently under investigation is REGN5668 (R5668), a bsAb designed to simultaneously bind MUC16 on tumor cells and CD28 on T-cells, thereby providing a co-stimulatory signal to enhance T-cell activation in the TME.